Antiviral Drug Screen Identifies DNA-Damage Response Inhibitor as Potent Blocker of SARS-CoV-2 Replication. Garcia et al

Published: 12 March 2021| Version 1 | DOI: 10.17632/vnwdznrsjb.1
Contributors:
, Arun Sharma, Arunachalam Ramaiah, Chandani Sen, Arunima Purkayastha, Donald Kohn, Mark Parcells, Sebastian Beck, Heeyoung Kim, Malina Bakowski, Melanie Kirkpatrick, Laura Riva, Karen Wolff, Brandon Han, Constance Yuen, David Ulmert, Prabhat Purbey, Phillip Scumpia, Nathan Beutler, Thomas Rogers, Arnab Chatterjee, Gülsah Gabriel, Ralf Bartenschlager, Brigitte Gomperts, Clive Svendsen, Ulrich Betz, Robert Damoiseaux, Vaithilingaraja Arumugaswami

Description

Supplemental Items.

Files

Institutions

University of California Los Angeles

Categories

High-Throughput Screening, DNA Damage Response, Protein Kinase Inhibitor, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19

Licence